In the pursuit of novel cancer therapeutics, PI3K/Akt inhibitors, crucial for disrupting cell growth and survival pathways, exhibit promise in specific cancer scenarios, especially in initial clinical phases and experimental studies. Here, AKT1 is linked to cancer.